#Canada #Duchesnay #Éric Gervais #Blainville #Pharma

Duchesnay Pharmaceutical Group: Celebrating a Decade of Resilience

Five years post-acquisition by senior management, Duchesnay Pharmaceutical Group (DPG) enjoys remarkable accomplishments. Founded in the 1970s, the company initially began as a family enterprise, gaining momentum in the early 1990s under the stewardship of President Éric Gervais. Under Gervais's leadership, DPG emerged as a pioneer in women's health, substantially enhancing its manufacturing capabilities. This journey led to substantial successes, particularly in the realm of innovative therapies addressing pregnancy-related nausea and vomiting.

An Inspiring Transition

In June 2021, following a buyout that transformed DPG's operational model, the management team embarked on ambitious growth plans. This event initiated a new chapter, establishing DPG as one of the few full-range pharmaceutical businesses in Canada. The company's strategic focus enabled it to expand its product catalog, enhance international exports, and increase employment significantly.

Today, DPG operates across the entire pharmaceutical spectrum. This includes research, development, manufacturing, and the international export of innovative treatments. The group has broadened its operations to include six companies spanning Canada and the United States, significantly amplifying its reach and capacity.

Expansion and Innovation

This expansion journey included the establishment of Duchesnay (Canada) and Duchesnay USA focused on improving women's health, alongside Medunik Canada and Medunik USA dedicated to combating rare diseases. Furthermore, Analog Pharma and Analog Pharma Canada specialize in orphan generic medications, providing a comprehensive approach to the pharmaceutical lifecycle.

Since the 2021 transition, the group has amplified its international presence by increasing its exports tenfold, now reaching markets in over 45 countries and aiming for 60 countries within the next two years. Such growth was fueled by tripling the annual tablet production to meet soaring global demand.

Employee Growth and Corporate Culture

DPG has witnessed a significant upswing in team size, doubling its workforce within five years. This development reflects the company's dedication to nurturing talent and fostering a workplace environment grounded in human values. Employees like Brigitte Chabot express pride in their contributions, emphasizing DPG’s support for personal and professional empowerment.

Recognizing its ongoing growth, DPG established an Advisory Board composed of diverse experts to navigate strategic direction and offer invaluable insights, demonstrating a proactive approach to its development. During celebratory events, including a motivational address from renowned businesswoman Danièle Henkel, the commitment of both staff and leadership to DPG's mission was reaffirmed.

Achievements since 2021

Duchesnay's advancements since the management transition are impressive, with eight new products launched and substantial investments made to enhance global market reach. Notably, 2023 saw DPG featured in the Canadian government's Global Hypergrowth Project, emphasizing the company’s role as a pivotal growth pillar in the national economy.

In 2024, DPG received the prestigious Innovation Award from ADRIQ, acknowledging its contributions to research and development. Furthermore, Gervais’s Prix Bernard-Landry award underlined his individual commitment to fostering Quebec’s research ecosystem.

The company is also engaged in ground-breaking research initiatives, such as a collaboration with the Population Council in New York to innovate treatments for conditions like multiple sclerosis — a disease that commonly affects women.

DPG is not only focused on market development but also prioritizes employee well-being, maintaining a balanced work-life culture that garnered recognition with the Concilivi seal, affirming its commitment to family-friendly practices.

Additionally, it received the Women in Governance's Parity Certification in 2024, showcasing its dedication to gender equality within leadership roles, with women holding six of the ten positions on the Executive Team.

Conclusion

As Duchesnay Pharmaceutical Group commemorates five years of sustained growth, its journey illustrates a blend of strategic vision, commitment to innovation, and a people-focused culture. Looking to the future, DPG is set to continue its impactful presence in both the Canadian and international pharmaceutical landscape, striving to enhance health outcomes and empower patients at every junction. For further information, visit Duchesnay Pharmaceutical Group.